These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 21855592

  • 21. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 22. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T, Forstén A, Arora A, Tsai T, Clemens R.
    Hum Vaccin Immunother; 2015 Sep 15; 11(8):2102-12. PubMed ID: 26091244
    [Abstract] [Full Text] [Related]

  • 23. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G.
    Vaccine; 2008 Dec 02; 26(51):6614-9. PubMed ID: 18930093
    [Abstract] [Full Text] [Related]

  • 24. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G.
    Hum Vaccin Immunother; 2014 Dec 02; 10(6):1701-10. PubMed ID: 24732325
    [Abstract] [Full Text] [Related]

  • 25. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.
    Vaccine; 2012 Jan 20; 30(5):936-40. PubMed ID: 22138210
    [Abstract] [Full Text] [Related]

  • 26. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, Kim SR, Kim WJ, Cheong HJ.
    J Med Virol; 2009 Apr 20; 81(4):722-7. PubMed ID: 19235853
    [Abstract] [Full Text] [Related]

  • 27. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.
    Vaccine; 2011 Nov 28; 29(51):9544-50. PubMed ID: 21986218
    [Abstract] [Full Text] [Related]

  • 28. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF, Zhang AJ, To KK, Chan JF, Li P, Wong TL, Zhang R, Chan TC, Chan BC, Wai HH, Chan LW, Fong HP, Hui RK, Kong KL, Leung AC, Ngan AH, Tsang LW, Yeung AP, Yiu GC, Yung W, Lau JY, Chen H, Chan KH, Yuen KY.
    Lancet Infect Dis; 2016 Feb 28; 16(2):209-18. PubMed ID: 26559482
    [Abstract] [Full Text] [Related]

  • 29. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2007 Sep 17; 25(37-38):6692-8. PubMed ID: 17697730
    [Abstract] [Full Text] [Related]

  • 30. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.
    Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angermayr R, Neugebauer J, Kirsten K, Förster-Waldl E, Koellges R, Ehrlich HJ, Barrett PN.
    Vaccine; 2012 Sep 07; 30(41):5956-66. PubMed ID: 22846396
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
    Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, Pinzani R, Zanetti A, Principi N.
    J Med Virol; 2006 Apr 07; 78(4):440-5. PubMed ID: 16482542
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, Thomas T, Liberty A, Treurnich F, Cutland CL, Weinberg A, Violari A.
    AIDS; 2013 Jan 28; 27(3):369-79. PubMed ID: 23032417
    [Abstract] [Full Text] [Related]

  • 33. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM.
    Pediatrics; 2005 Apr 28; 115(4):1039-47. PubMed ID: 15805382
    [Abstract] [Full Text] [Related]

  • 34. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients.
    Manuel O, Humar A, Berutto C, Ely L, Giulieri S, Lien D, Meylan PR, Weinkauf J, Pascual M, Nador R, Aubert JD, Kumar D.
    J Heart Lung Transplant; 2011 Jun 28; 30(6):679-84. PubMed ID: 21377898
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

  • 36. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
    Sugimura T, Ito Y, Tananari Y, Ozaki Y, Maeno Y, Yamaoka T, Kudo Y.
    Vaccine; 2008 May 23; 26(22):2700-5. PubMed ID: 18436353
    [Abstract] [Full Text] [Related]

  • 37. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2013 Dec 05; 31(50):6034-40. PubMed ID: 24055306
    [Abstract] [Full Text] [Related]

  • 38. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G.
    N Engl J Med; 2004 Nov 25; 351(22):2286-94. PubMed ID: 15525713
    [Abstract] [Full Text] [Related]

  • 39. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 25; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 40. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P.
    Vaccine; 2017 Dec 19; 35(52):7339-7346. PubMed ID: 29157960
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.